Dr Mark Best
Pharmacy and Biomolecular Sciences
I graduated from the University of Reading in 2006 with a BSc Biotechnology, before carrying out research roles within industry. Firstly, at GlaxoSmithKline’s New Frontiers research and development site in Harlow (UK), where I worked as an assay development scientist tasked with converting HPLC methods to a new high-throughput system: the first of its kind in Europe.
After this, I returned to Ludger Ltd., a bioscience company in Oxford that specialise in glycobiology research and glycoprofiling services, and also the company where I spent an industrial placement year during my undergraduate studies. At Ludger, I was tasked with developing new glycobiology analysis tools that were added to the company’s portfolio of products and services. I am currently back in academia, working under Professor Matteo Santin, with his current research focused on the synthesis and characterisation of hyper-branched peptide materials (dendrons) and nano-sized biomaterials. These are investigated for a diverse array of applications, on projects looking at improving biomimicry, cell encapsulation, 3-D bioplotting and many other aspects of tissue regeneration.
Nanomaterial characterisation, formulation, QC and safety evaluation.
Awarded IVTS Student bursary prize at the annual conference 2011 for a poster presentation entitled: Investigating the toxicity of putative antimicrobial nanoparticles on oral epithelial keratinocytes.